Developing a gene therapy is not only about designing a therapeutic vector. Understanding what is produced, how consistently it is produced, and how its critical characteristics are measured is equally important.
Adeno-associated virus (AAV) vectors have become an important platform in genetic medicine research. Their ability to deliver genetic material to target tissues has supported the investigation of therapies for a range of inherited and other serious conditions. Yet promising biology alone is not sufficient to move a potential therapy from the laboratory toward clinical evaluation. The characteristics and consistency of the investigational product also matter.
Knowing What Is in the Product
Product characterization begins with questions that appear simple but require carefully selected analytical methods: Is the intended vector present? How much vector genome is present? What impurities remain from production? Is the packaged genetic material consistent with the intended design?
For AAV-based products, analytical approaches may address vector identity, genome titer, capsid characteristics, residual process-related materials, and genome integrity. Different methods provide different types of information. A coordinated analytical strategy is therefore more informative than relying on any one test in isolation.
Why Consistency Is Essential
Manufacturing processes can evolve substantially during development. Changes in scale, materials, equipment, and purification strategies may influence product attributes. A key objective of process development is to understand and control relevant sources of variability so that data generated at different stages of a program remain interpretable.
Consistency does not mean that every early-stage process must already resemble commercial manufacturing. Instead, the degree of process understanding and analytical control should grow alongside the development program and its intended clinical use.
Potency and Product-Related Attributes
Measuring vector genomes alone does not establish biological activity. A potency assessment seeks to provide evidence that a product can perform an intended biological function, using methods suited to its mechanism of action and stage of development.
Additional product-related attributes, such as vector genome composition and stability, may also be important to investigate.
Because the relevant risks and performance characteristics differ across products, quality strategies must be tailored rather than copied wholesale from another vector or therapeutic platform.
Quality as Part of Translation
Scientific discovery, nonclinical evaluation, analytical development, and clinical planning are interconnected. Questions about identity, purity, strength, and potency are therefore best considered throughout development—not only just before a clinical milestone.
Regulatory authorities likewise emphasize a phase-appropriate, product-specific approach to chemistry, manufacturing, and controls (CMC).
At Exir Gene Pharmed, we regard scientific rigor and quality-focused development as central principles in the pursuit of genetic medicines for patients with unmet medical needs.